Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists

被引:20
|
作者
Pal, Shantanu [1 ,2 ]
Choi, Won Jun [1 ,2 ]
Choe, Seung Ah [1 ,2 ]
Heller, Cara L. [3 ]
Gao, Zhan-Guo [3 ]
Chinn, Moshe [3 ]
Jacobson, Kenneth A. [3 ]
Hou, Xiyan [1 ,2 ]
Lee, Sang Kook [1 ,2 ]
Kim, Hea Ok [1 ,2 ]
Jeong, Lak Shin [1 ,2 ]
机构
[1] Ewha Womans Univ, Coll Pharm, Med Chem Lab, Dept Bioinspired Sci, Seoul 120750, South Korea
[2] Ewha Womans Univ, Coll Pharm, Med Chem Lab, Div Life & Pharmaceut Sci, Seoul 120750, South Korea
[3] NIDDKD, NIH, Mol Recognit Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA
关键词
A(3) Adenosine receptor; Antagonists; Truncated adenosine; Structure-activity relationships; LIGANDS; CELLS; INHIBITION;
D O I
10.1016/j.bmc.2009.03.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
On the basis of potent and selective binding affinity of truncated 4'-thioadenosine derivatives at the human A(3) adenosine receptor (AR), their bioisosteric 4'-oxo derivatives were designed and synthesized from commercially available 2,3-O-isopropylidene-D-erythrono lactone. The derivatives tested in AR binding assays were substituted at the C2 and N-6 positions. All synthesized nucleosides exhibited potent and selective binding affinity at the human A(3) AR. They were less potent than the corresponding 4'-thio analogues, but showed still selective to other subtypes. The 2-Cl series generally were better than the 2-H series in view of binding affinity and selectivity. Among compounds tested, compound 5d (X=Cl, R=3-bromobenzyl) showed the highest binding affinity (K-i = 13.0 +/- 6.9 nM) at the hA(3) AR with high selectivity (at least 88-fold) in comparison to other AR subtypes. Like the corresponding truncated 4'-thio series, compound 5d antagonized the action of an agonist to inhibit forskolin-stimulated adenylate cyclase in hA(3) AR-expressing CHO cells. Although the 4'-oxo series were less potent than the 4'-thio series, this class of human A(3) AR antagonists is also regarded as another good template for the design of A(3) AR antagonists and for further drug development. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3733 / 3738
页数:6
相关论文
共 50 条
  • [31] Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists
    Müller, CE
    Geis, U
    Hipp, J
    Schobert, U
    Frobenius, W
    Pawlowski, M
    Suzuki, F
    Sandoval-Ramírez, J
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (26) : 4396 - 4405
  • [32] Structure-activity relationship of N6-substituted D-4′-thioadenosine derivatives as potent and selective agonists at the human A3 adenosine receptor.
    Jeong, LS
    Shin, DH
    Kim, HO
    Jung, JY
    Kim, HJ
    Kim, WK
    Melman, N
    Gao, ZG
    Jacobson, KA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U54 - U54
  • [33] Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques
    Bhattacharya, P
    Leonard, JT
    Roy, K
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (04) : 1159 - 1165
  • [34] N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor
    Volpini, Rosaria
    Dal Ben, Diego
    Lambertucci, Catia
    Taffi, Sara
    Vittori, Sauro
    Klotz, Karl-Norbert
    Cristalli, Gloria
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (06) : 1222 - 1230
  • [35] The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor
    DeNinno, MP
    Masamune, H
    Chenard, LK
    DiRico, KJ
    Eller, C
    Etienne, JB
    Tickner, JE
    Kennedy, SP
    Knight, DR
    Kong, J
    Oleynek, JJ
    Tracey, WR
    Hill, RJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (09) : 2525 - 2527
  • [36] Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity (vol 66, pg 12249, 2023)
    Kim, Gibae
    Hou, Xiyan
    Byun, Woong Sub
    Kim, Gyudong
    Jarhad, Dnyandev B.
    Lee, Grim
    Hyun, Young Eum
    Yu, Jinha
    Lee, Chang Soo
    Qu, Shuhao
    Warnick, Eugene
    Gao, Zhan-Guo
    Kim, Ji Yong
    Ji, Seunghee
    Shin, Hyunwoo
    Choi, Jong-Ryoul
    Jacobson, Kenneth A.
    Lee, Hyuk Woo
    Lee, Sang Kook
    Jeong, Lak Shin
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 2236 - 2236
  • [37] Synthesis of hypermodified adenosine derivatives as selective adenosine A3 receptor ligands
    Cosyn, L
    Gao, ZG
    Van Rompaey, P
    Lu, CR
    Jacobson, KA
    Van Calenbergh, S
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (05) : 1403 - 1412
  • [38] 4′-tetrazolyl-alkyl-N6-substituted adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists
    Petrelli, Riccardo
    Torquati, Ilaria
    Luongo, Livio
    Guida, Francesca
    Boccella, Serena
    Lavecchia, Antonio
    Klotz, Karl-Norbert
    Kachler, Sonja
    Franchetti, Palmarisa
    Grifantini, Mario
    Maione, Sabatino
    Cappellacci, Loredana
    [J]. PURINERGIC SIGNALLING, 2014, 10 (04) : 775 - 775
  • [39] Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A(3) adenosine receptor antagonists
    Jiang, JL
    vanRhee, AM
    Chang, L
    Patchornik, A
    Ji, XD
    Evans, P
    Melman, N
    Jacobson, KA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (16) : 2596 - 2608
  • [40] 7-deazaadenines bearing polar substituents:: Structure-activity relationships of new A1 and A3 adenosine receptor antagonists
    Hess, S
    Müller, CE
    Frobenius, W
    Reith, U
    Klotz, KN
    Eger, K
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) : 4636 - 4646